National Health Service Setting Research Articles

Estimating the impact on patient safety of enabling the digital transfer of patients’ prescription information in the English NHS

ObjectivesTo estimate the number and burden of medication errors associated with prescription information transfer within the National Health Service (NHS) in England and the impact of implementing an interoperable prescription...

Development and evaluation of machine-learning methods in whole-body magnetic resonance imaging with diffusion weighted imaging for staging of patients with cancer: the MALIBO diagnostic test accuracy study

Background Whole-body magnetic resonance imaging is accurate, efficient and cost-effective for cancer staging. Machine learning may support radiologists reading whole-body magnetic resonance imaging. Objectives To develop a machine-learning algorithm to detect normal organs and cancer lesions. To compare diagnostic accuracy, time and agreement of radiology reads to detect metastases using whole-body magnetic resonance imaging with concurrent machine learning (whole-body magnetic resonance imaging + machine learning) against standard whole-body magnetic resonance imaging (whole-body magnetic resonance imaging + standard deviation). Design and participants Retrospective analysis of (1) prospective single-centre study in healthy volunteers > 18 years (n = 51) and (2) prospective multicentre STREAMLINE study patient data (n = 438). Tests Index: whole-body magnetic resonance imaging + machine learning. Comparator: whole-body magnetic resonance imaging + standard deviation. Reference standard Previously established expert panel consensus reference at 12 months from diagnosis. Outcome measures Primary: difference in per-patient specificity between whole-body magnetic resonance imaging + machine learning and whole-body magnetic resonance imaging + standard deviation. Secondary: per-patient sensitivity, per-lesion sensitivity and specificity, read time and agreement. Methods Phase 1: classification forests, convolutional neural networks, and a multi-atlas approaches for organ segmentation. Phase 2/3: whole-body magnetic resonance imaging scans were allocated to Phase 2 (training = 226, validation = 45) and Phase 3 (testing = 193). Disease sites were manually labelled. The final algorithm was applied to 193 Phase 3 cases, generating probability heatmaps. Twenty-five radiologists (18 experienced, 7 inexperienced in whole-body magnetic resonance imaging) were randomly allocated whole-body magnetic resonance imaging + machine learning or whole-body magnetic resonance imaging + standard deviation over two or three rounds in a National Health Service setting. Read time was independently recorded. Results Phases 1 and 2: convolutional neural network had best Dice similarity coefficient, recall and precision measurements for healthy organ segmentation. Final algorithm used a ‘two-stage’ initial organ identification followed by lesion detection. Phase 3: evaluable scans (188/193, of which 50 had metastases from 117 colon, 71 lung cancer cases) were read between November 2019 and March 2020. For experienced readers, per-patient specificity for detection of metastases was 86.2% (whole-body magnetic resonance imaging + machine learning) and 87.7% (whole-body magnetic resonance imaging + standard deviation), (difference −1.5%, 95% confidence interval −6.4% to 3.5%; p = 0.387); per-patient sensitivity was 66.0% (whole-body magnetic resonance imaging + machine learning) and 70.0% (whole-body magnetic resonance imaging + standard deviation) (difference −4.0%, 95% confidence interval −13.5% to 5.5%; p = 0.344). For inexperienced readers (53 reads, 15 with metastases), per-patient specificity was 76.3% in both groups with sensitivities of 73.3% (whole-body magnetic resonance imaging + machine learning) and 60.0% (whole-body magnetic resonance imaging + standard deviation). Per-site specificity remained high within all sites; above 95% (experienced) or 90% (inexperienced). Per-site sensitivity was highly variable due to low number of lesions in each site. Reading time lowered under machine learning by 6.2% (95% confidence interval −22.8% to 10.0%). Read time was primarily influenced by read round with round 2 read times reduced by 32% (95% confidence interval 20.8% to 42.8%) overall with subsequent regression analysis showing a significant effect (p = 0.0281) by using machine learning in round 2 estimated as 286 seconds (or 11%) quicker. Interobserver variance for experienced readers suggests moderate agreement, Cohen’s κ = 0.64, 95% confidence interval 0.47 to 0.81 (whole-body magnetic resonance imaging + machine learning) and Cohen’s κ = 0.66, 95% confidence interval 0.47 to 0.81 (whole-body magnetic resonance imaging + standard deviation). Limitations Patient whole-body magnetic resonance imaging data were heterogeneous with relatively few metastatic lesions in a wide variety of locations, making training and testing difficult and hampering evaluation of sensitivity. Conclusions There was no difference in diagnostic accuracy for whole-body magnetic resonance imaging radiology reads with or without machine-learning support, although radiology read time may be slightly shortened using whole-body magnetic resonance imaging + machine learning. Future work Failure-case analysis to improve model training, automate lesion segmentation and transfer of machine-learning techniques to other tumour types and imaging modalities. Study registration This study is registered as ISRCTN23068310. Funding This award was funded by the National Institute for Health and Care Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme (NIHR award ref: 13/122/01) and is published in full in Efficacy and Mechanism Evaluation; Vol. 11, No. 15. See the NIHR Funding and Awards website for further award information.

Subarachnoid haemorrhage in the emergency department (SHED): a prospective, observational, multicentre cohort study

BackgroundPeople presenting to the ED with acute severe headache often undergo investigation to exclude subarachnoid haemorrhage (SAH). International guidelines propose that brain imaging within 6 hours of headache onset can...

Development of an intervention for patients following an anterior cruciate ligament rupture: an online nominal group technique consensus study

Objectives(1) To develop an intervention for to support patients diagnosed with an anterior cruciate ligament (ACL) rupture with decision-making regarding treatment. (2) To define evidence-based recommendations for the treatment of...

Online peer support groups for individuals who hear voices: protocol for a nonrandomised feasibility study

ABSTRACT Background Hearing Voices Groups (HVGs) have proliferated internationally. They are premised on the notion that connections between peers facilitate personal recovery. Little systematic research exists into if, and how, HVGs may be effective, especially when convened online. This paper aims to harmonise standardised research methodology with the liberatory, survivor-led ethos of many HVGs to outline a protocol for the first longitudinal, nonrandomised trial of an online HVG to take place within UK mental health services. Methods Six to ten adults who hear voices will be recruited from both community and UK National Health Service (NHS) settings to participate in a six-month peer-support group that is delivered via videoconference. Participants will complete questionnaires assessing social support, voice-hearing and feelings of personal recovery and qualitative interviews at baseline and at the end of the group. Participants will also complete measures of group cohesion at weeks 4 and 12. Results Data will be analysed for feasibility, acceptability and safety. Discussion This is the first longitudinal study evaluating the feasibility and acceptability of an online HVG held within the NHS. The findings may provide insights into the impact of such interventions and inform the design of a future, definitive study.

Reviewing past and present consent practices in unplanned obstetric interventions: an eye towards the future

Many first-time mothers (primiparous) within UK National Health Service (NHS) settings require an obstetric intervention to deliver their babies safely. While the antepartum period allows time for conversations about consent...

Oral ethanol prescribing for alcohol withdrawal syndrome: initial findings and future directions following implementation within a United Kingdom National Health Service setting

Introduction Prescribing of ethanol may be an alternative to benzodiazepines for managing alcohol withdrawal syndrome. We present our experience of oral ethanol prescribing within an acute United Kingdom National Health Service setting. Methods A retrospective review of patients presenting with alcohol withdrawal who were managed with oral ethanol or benzodiazepines was performed from data collected across two acute care settings. Ethanol prescribing inclusion: high risk of delirium tremens, or a history of harmful alcohol consumption (typically ≥30 units/day; in which 1 unit = 8 grams of alcohol; one standard United States drink = 14 grams of alcohol) or known to have a history of severe alcohol withdrawal, alcohol-related seizures or delirium tremens. Inverse propensity score weighting was used to partially account for variance between the two patient populations. Results Fifty (82 per cent male; average age 50.9 years) and 93 (84 per cent male; average age 46.5 years) patients in receipt of benzodiazepines or ethanol, respectively, were included. The likelihood of hospital admission was significantly reduced when individuals were managed with ethanol (odds ratio 0.206 (95 per cent confidence interval; 0.066-0.641), Wald chi-square P = 0.006). In those not admitted, the treatment type had no significant impact on length of stay or the number of occasions a pharmacological agent was required. In those admitted, treatment had no significant effect on length of stay. Discussion We offer preliminary evidence to support a role of oral ethanol in the management of patients with alcohol withdrawal. We have implemented a robust and translatable guideline. Despite limitations in the data set the impact of ethanol in reducing the likelihood of admission remained significant. Conclusions In individuals at significant risk of severe alcohol withdrawal, prescribing ethanol as part of a comprehensive care plan, may reduce unplanned admissions. The preliminary findings presented here warrant further assessment through prospective studies.

Developing a career and education framework for advanced clinical practice in midwifery.

This study outlines the nature of Advanced Clinical Practice in Midwifery (ACPiM), reporting on a stakeholder analysis as part of a national project to develop a career framework for advanced practice in midwifery on behalf of the National Health Service (NHS) in England. Between June and July 2022, 31 advanced practice midwives were recruited across England within the NHS settings. Convenience sampling was used to identify midwives working as advanced practitioners, and those pursuing this career route. Focus group and one-to-one interviews were conducted, recorded, and transcribed. These stakeholder data were then analyzed using a reflexive thematic approach. ACP midwives were active across many professional settings. The findings resulted in three themes: Midwifery autonomy, Desire for progression, and Avenues of support. Midwifery autonomy highlighted a midwifery desire to utilize specialist skills and expert decision-making to provide holistic care directly to women and families. Desire for progression highlighted that, regardless of career stage, midwives aspired to advance their practice requiring a range of pathways to fulfil career satisfaction and meet local population health needs. Avenues of support discussed the barriers and facilitators to progression, highlighting the need for service vision, a multi-disciplinary approach to facilitate support for individuals, and strong midwifery leadership. Although the ACPiM role is desired by maternity institutions and organizations, midwives remain unclear about how to achieve this position, and employers remain unsure of how an ACPiM could transform services. If midwives are to successfully achieve ACPiM status, organizational support is needed to facilitate individuals drive for career progression, resulting in a strengthened workforce and improved patient experience.

FEASIBILITY STUDY TO ASSESS THE DELIVERY OF A NOVEL ISOMETRIC EXERCISE INTERVENTION FOR PEOPLE WITH STAGE 1 HYPERTENSION

Objective: Adherence is low to the lifestyle changes recommended by NICE for patients with hypertension. More easily adopted, effective and manageable exercise interventions are needed. This study determined the feasibility of personalised isometric exercise (IE) for patients with Stage (grade) 1 hypertension in the National Health Service (NHS) in England. Design and method: We conducted a multicentre randomised controlled feasibility study delivered through NHS primary/secondary care. Patients included were 18+, with clinic systolic BP (SBP)140-159mmHg, not on anti-hypertensive medication and without significant medical contraindications. Participants were randomised to standard lifestyle advice (control) or standard lifestyle advice plus wall squat IE for a 6-month period (intervention). After excluding people with average home systolic <135mmHg, 41 participants were included (control n=19, IE n=22) (aged 57 ± 15.15yrs). Participants were followed up at 4-weeks, 3-months, and 6-months. Results: Healthcare professionals were able to deliver the intervention with high fidelity (100% passed independent delivery check and 84.6% of participants recorded at least 2/3 of exercise heart rates within their target range over 6 months). A sample size for an efficacy trial (primary objective), was determined n= 542, based upon the 35% attrition rate and 14.4mmHg SD of change of SBP from baseline. Qualitative work provided valuable insights into acceptability, feasibility, delivery, and implementation in an NHS setting and for improved follow-on studies. Whilst the study was not powered to detect BP changes, reductions in SBP were observed at all time points. Figure 1. Marginal means and 95% CI from ANCOVA (Per-protocol population) Difference between means at each time point were: 4-weeks -2.31 mmHg (95% CI -11.29 to 6.67), 3 months -4.07 mmHg (95% CI, -10.28 to 2.15) 6 months -2.35 (95% CI -11.70-6.99). Pilot economic analyses suggested the intervention is cost-effective. Conclusions: Feasibility of IE has been demonstrated, but deliverability without significant modifications to the wall squat IE prescription protocol due to current NHS constraints would not be possible. Findings support investigating effectiveness of the intervention and justify a full RCT. A sample size of n=542 is needed to establish effectiveness.

Wales Infants’ and childreN’s Genome Service (WINGS): providing rapid genetic diagnoses for unwell children

IntroductionThis study reviews the first 3 years of delivery of the first National Health Service (NHS)-commissioned trio rapid whole genome sequencing (rWGS) service for acutely unwell infants and children in...

AI-Enhanced Healthcare: Not a new Paradigm for Informed Consent.

With the increasing prevalence of artificial intelligence (AI) and other digital technologies in healthcare, the ethical debate surrounding their adoption is becoming more prominent. Here I consider the issue of gaining informed patient consent to AI-enhanced care from the vantage point of the United Kingdom's National Health Service setting. I build my discussion around two claims from the World Health Organization: that healthcare services should not be denied to individuals who refuse AI-enhanced care and that there is no precedence to seeking patient consent to AI-enhanced care. I discus U.K. law relating to patient consent and the General Data Protection Regulation to show that current standards relating to patient consent are adequate for AI-enhanced care. I then suggest that in the future it may not be possible to guarantee patient access to non-AI-enhanced healthcare, in a similar way to how we do not offer patients manual alternatives to automated healthcare processes. Throughout my discussion I focus on the issues of patient choice and veracity in the patient-clinician relationship. Finally, I suggest that the best way to protect patients from potential harms associated with the introduction of AI to patient care is not via an overly burdensome patient consent process but via evaluation and regulation of AI technologies.

Assessment of Dementia in Minority Ethnic Groups in Scotland: Results of a Survey of Cognitive Specialists.

Minority ethnic groups (MEGs) in Europe receive suboptimal dementia evaluation, yet related research in Scotland is lacking. This research examined the evaluation of dementia in MEGs in Scotland and compared it with previous research to highlight the changes in the clinical evaluation of dementia over the decade. A self-administered survey was created online and emailed to 14 Heads of the boards under the Scottish National Health Service and dementia-associated settings and organizations. Most surveyed centers (85.6%) received MEG referrals. Although 92.9% of the centers used professional translators when needed, 85.7% thought assessing dementia in MEGs was difficult, mostly due to the suitability of test instruments and rating scales and patients' linguistic abilities. Very few found their skills to be good in evaluating MEGs. There was no mention of specialized dementia services for MEGs. The lack of culturally appropriate instruments and specialized dementia services reveals that the services are not ready to meet the demand for evaluating patients from diverse cultural and language backgrounds. Inadequate clinical evaluation may lead to misdiagnoses. Therefore, although significant work has been carried out in the past few years, improvements must be continued to enhance the current practices and apply suitable evaluation methods for MEGs.

Economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from an English National Health Service perspective

IntroductionThree recent randomised controlled trials have demonstrated that pulmonary vein isolation as an initial rhythm control strategy with cryoablation reduces atrial arrhythmia recurrence in patients with symptomatic paroxysmal atrial fibrillation...

Key considerations when developing and implementing digital technology for early detection of dementia causing diseases: a qualitative study

Abstract Introduction There has been substantial growth in research exploring use of digital health technologies (DHT) to improve global population health. Harnessing the potential of DHT for the early detection of neurodegenerative diseases is one such area.1 According to the National Institute for Health and Care Excellence, DHTs need to be credible for UK Healthcare Professionals (HCPs); HCPs should be involved in the development and implementation process of DHTs to ensure that their needs are met and to promote the successful adoption into healthcare systems.2 Aim To explore HCPs’ perspectives on key considerations of developing and implementing DHT for the early detection of dementia causing diseases, such as Alzheimer’s, within the National Health Service (NHS). Methods Ethical approval was granted from Newcastle University Ethics Committee. HCPs with patient-facing roles within primary or secondary care NHS settings were recruited through various online networks alongside a snowball sampling approach. Participants took part in a semi-structured audio-recorded interview exploring their experience of current diagnostic practices, opinions on the early detection of dementia causing diseases and the use of DHT to aid this approach, and the challenges of implementing such interventions into healthcare. The framework approach was used to thematically analyse the verbatim transcripts to identify core concepts and themes emerging within the interviews. A list of core concepts and themes was applied systematically to the whole data set using QSR N-Vivo (Version 1.6.1). The research team then used the ‘constant comparison’ technique to move backwards and forwards between these data and evolve explanations until a fit was made. Results Eighteen interviews were conducted with 11 primary and seven secondary care HCPs. Our analysis highlighted three core concepts, centring around considerations for healthcare service users, HCPs, and the DHT when developing and implementing DHT for the early detection of dementia causing diseases. HCPs recognised the potential benefits of providing an early detection of dementia causing diseases to healthcare services users, but only if a suitable intervention was available to allow individuals to potentially reduce their risk. Additionally, HCPs were concerned about the impact on health inequity, such as accessibility of this type of service to individuals who have disabilities or could be possibly digitally excluded. Many HCPs were also concerned about the impact on the healthcare system, with fears that it could overburden the NHS if sufficient resources and support were not provided for its implementation. In regard to the DHT, HCPs were positive about the possibility of a DHT to remotely capture real time data and felt it would be important to capture different modalities to help differentiate between dementia causing diseases. Discussion/Conclusion This study highlights the need to design a DHT for the early detection of dementia causing diseases that is accessible to users, to promote health equity. This study also highlights potential barriers for researchers when implementing a DHT into the NHS, although it cannot be assumed that these are the only barriers that may be encountered; developers will need to consider this so that a future DHT meet HCPs’ needs.

UK trial of pressurised intraperitoneal aerosolised chemotherapy (PIPAC) with oxaliplatin for colorectal cancer peritoneal metastases (NCT03868228).

This is the first UK trial of pressurised intraperitoneal aerosolised chemotherapy (PIPAC) for colorectal cancer peritoneal metastases. This trial aimed to assess the impact of PIPAC in combination with standard of care systemic treatment on: progression free survival (PFS); quality of life (QoL); and short-term complications. In addition, this trial set out to demonstrate that PIPAC can be performed safely in operating theatres within a National Health Service (NHS) setting. Single-centre clinical trial with prospective data collection for patients undergoing 8-weekly PIPAC with oxaliplatin at 92 mg/m2 from January 2019 till January 2022. Progression free survival was assessed using peritoneal carcinomatosis index (PCI) by CT scans and laparoscopy. Quality of life was assessed by EORTC QLQ-C30 questionnaire. Adverse events were recorded using CTCAE. Five patients underwent a total of ten PIPAC administrations (median 2, range 1-4). Median PFS was 6.0months. QoL was maintained across repeat PIPAC procedures but a decrease in social functioning and increased fatigue were evident. Three incidences of grade 3 adverse events occurred but PIPAC was well tolerated. The presented data demonstrates that PIPAC is feasible and can be safely delivered within the NHS for patients with colorectal cancer peritoneal metastases, but caution must also be exercised given a risk of adverse events. Systemic chemotherapy can be safely administered at a different unit to the PIPAC procedure if both groups have clear lines of communication and timely data sharing.

Exploration of the representation of the allied health professions in senior leadership positions in the UK National Health Service

BackgroundAllied health professionals (AHPs) are an important group within the National Health Service (NHS) in the UK and make up a large portion of the workforce. Investment in AHP leadership...

Qualified and motivated, but limited by specialty-specific barriers: a national survey of UK Palliative Medicine consultants research experience

ObjectivesProviding high-quality safe palliative care requires high-quality clinically driven research. Little is known about how to optimise clinical research capacity in this field.To understand interest and capacity to conduct clinical...

Medicalisation of vaping in the UK? E-cigarette users' perspectives on the merging of commercial and medical routes to vaping.

In the UK, most smokers choosing e-cigarettes to quit smoking will access vaping via commercial routes. In recent years, however, a shift towards medicalisation of vaping has become apparent, with public health guidance supporting e-cigarettes for smoking cessation and increased partnership working between healthcare professionals and the vaping industry. To achieve the UK's Smokefree 2030 target, the UK Government has set out measures to use e-cigarettes in National Health Service (NHS) settings and to move towards streamlining processes to make e-cigarettes available to a million smokers. This article aims to understand acceptability of different approaches by seeking perspectives of people with lived experience of e-cigarette use for smoking cessation. Mixed methods data collected between March 2018 and March 2019 as part of a broader study of e-cigarette use trajectories (ECtra study). Data here relate to the views of partnership working and medicalisation of vaping extracted from 136 interviews/extended surveys of people who had used e-cigarettes to try to stop smoking. Qualitative data were thematically analysed. Participant ratings of interventions were presented descriptively, and differences in participant characteristics and ratings were reported. Three qualitative themes were identified: pro-partnership, anti-partnership and medicalisation dissonance. Medicalisation was discussed for its potential to reassure smokers about e-cigarette harms and its potential to reach smokers from disadvantaged backgrounds. Concerns were raised about cost-effectiveness, quality of support, conflicts of interest and limiting product choice. Most participants rated interventions involving partnership working as potentially helpful in switching from smoking to vaping. There were no statistically significant associations between age, gender and socioeconomic status, and helpfulness ratings. Both commercial and medical routes to vaping offer perceived benefits to vapers and may complement and reinforce each other to support smoking cessation.

Trauma-specific mindfulness-based cognitive therapy for women with post-traumatic stress disorder and a history of domestic abuse: intervention refinement and a randomised feasibility trial (coMforT study)

BackgroundWomen who have experienced domestic violence and abuse (DVA) are at increased risk of developing post-traumatic stress disorder (PTSD) and complex PTSD (CPTSD). In 2014–2015, we developed a prototype trauma-specific mindfulness-based cognitive therapy curriculum (TS-MBCT) for the treatment of PTSD in a DVA population. This study aimed to refine the prototype TS-MBCT and evaluate the feasibility of conducting a randomised controlled trial (RCT) testing its effectiveness and cost-effectiveness.MethodsIntervention refinement phase was informed by evidence synthesis from a literature review, qualitative interviews with professionals and DVA survivors, and a consensus exercise with experts in trauma and mindfulness. We tested the refined TS-MBCT intervention in an individually randomised parallel group feasibility trial with pre-specified progression criteria, a traffic light system, and embedded process and health economics evaluations.ResultsThe TS-MBCT intervention consisted of eight group sessions and home practice. We screened 109 women in a DVA agency and recruited 20 (15 TS-MBCT, 5 self-referral to National Health Service (NHS) psychological treatment), with 80% follow-up at 6 months. Our TS-MBCT intervention had 73% uptake, 100% retention, and high acceptability. Participants suggested recruitment via multiple agencies, and additional safety measures. Randomisation into the NHS control arm did not work due to long waiting lists and previous negative experiences. Three self-administered PTSD/CPTSD questionnaires produced differing outcomes thus a clinician administered measure might work better. We met six out of nine feasibility progression criteria at green and three at amber targets demonstrating that it is possible to conduct a full-size RCT of the TS-MBCT intervention after making minor amendments to recruitment and randomisation procedures, the control intervention, primary outcomes measures, and intervention content. At 6 months, none of the PTSD/CPTSD outcomes ruled out a clinically important difference between trial arms indicating that it is reasonable to proceed to a full-size RCT to estimate these outcomes with greater precision.ConclusionsA future RCT of the coMforT TS-MBCT intervention should have an internal pilot, recruit from multiple DVA agencies, NHS and non-NHS settings, have an active control psychological treatment, use robust randomisation and safety procedures, and clinician-administered measures for PTSD/CPTSD.Trial registrationISRCTN64458065 11/01/2019.

An economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from an English NHS perspective

Abstract Funding Acknowledgements Type of funding sources: Other. Main funding source(s): This cost-effectiveness study was funded by Medtronic Background The UK National Institute of Care Excellence (NICE) recommend the use of pulmonary vein isolation (PVI) to treat paroxysmal atrial fibrillation (PAF) in those who have not responded to drug treatment. Recently, three randomized controlled trials have demonstrated that as an initial rhythm control strategy, PVI with cryoballoon ablation, reduces atrial arrhythmia recurrence compared to antiarrhythmic drug (AAD) therapy in patients with symptomatic PAF. Purpose To evaluate the cost-effectiveness of first-line cryoablation versus first-line optimized AADs in an English National Health Service (NHS) setting. Methods Individual patient-level data from 703 participants with untreated PAF recruited into Cryo-FIRST, STOP AF First and EARLY-AF were used to derive equations to predict the following outcomes: rates of ablation, AF recurrence and resolution, AF-related hospital attendance, and health-related quality of life (HRQoL) utilities. Where parameters could not be sourced from the trial data, inputs were taken from the published literature or derived using clinical expert opinion. The cost-effectiveness model (CEM) was a hybrid of a decision tree with a one-year time horizon and a Markov model (three-month cycle length) with a lifetime time horizon and was developed from the perspective of the English NHS. Health benefits were expressed in quality-adjusted life years (QALYs), and all benefits and costs were discounted at 3.5% per year in line with NICE requirements. Uncertainty in the CEM inputs was explored using probabilistic sensitivity analysis. The results include an initial 12-week blanking period for all studies. Results The three-monthly rate of AF recurrence was reduced on average by 46.7% (p<0.001) in those treated with cryoablation. Similarly, the monthly rate of receiving an ablation following initial treatment was reduced by 72.8% (p<0.001) in the cryoablation arm. Furthermore, the average cryoablation patient was associated with a 4.3% (p=0.025) increase in their HRQoL. While the likelihood of failure was greater in the AAD group, in those who failed initial treatment, there was no difference in the rate of AF symptom resolution. The CEM indicates that cryoablation is more effective (+0.17 QALYs) and more costly (+£1,414) over a lifetime compared to optimized AADs. Cryoablation resulted in an Incremental Cost-Effectiveness Ratio of £8,435 with a 78.5% probability of being cost-effective at a willingness-to-pay threshold of £20,000 per QALY gained. Individuals in both treatment arms were predicted to receive ~1.2 ablations over a lifetime regardless of initial treatment. However, there was a 45% relative reduction in the amount of time spent in symptomatic AF states for those initially treated with cryoablation. Conclusions AF rhythm control in drug naïve patients with cryoballoon ablation is cost-effective compared to optimized AADs in an English NHS setting.